Case Number 6481
Request Date 16/01/2019
Completion Date 31/01/2019

 

Details of the Request

In your trust how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 6 months, latest 6 months that you can provide

Please provide the number of patients by treatment for the following disease modifying drugs.

  • Aubagio (teriflunomide)
  • Avonex (interferon b)
  • Betaferon (interferon beta-1b)
  • Brabio (glatiramer acetate)
  • Cladribine (Mavenclad)
  • Copaxone (glatiramer acetate)
  • Daclizumab (Zinbryta)
  • Extavia (beta interferon-1b)
  • Gilenya (fingolimod)
  • Lemtrada (alemtuzumab)
  • Ocrevus (Ocrelizumab)
  • Peginterferon beta-1a (Plegridy)
  • Rebif (beta interferon-1a)
  • Tecfidera (dimethyl fumarate)
  • Tysabri (natalizumab)
  • Others
  • Ampyra (Fampyra)

 

Details of the Response

The data has been run for the past six months from 01/06/2018 to 31/12/2018 with the following results:

Disease Modifying Drug Number of Patients
Aubagio (teriflunomide) 12
Avonex (interferon beta-1a) 8
Betaferon (interferon beta-1b) 0
Cladribine (Mavenclad) 0
Copaxone (glatiramer acetate) 41
Daclizumab (Zinbryta) 0
Extavia (beta interferon-1b) 0
Gilenya (fingolimod) 40
Glatiramer acetate generic [eg Brabio] 0
Lemtrada (alemtuzumab) 1
Ocrevus (Ocrelizumab) 0
Peginterferon beta-1a (Plegridy) 6
Rebif (beta interferon-1a) 13
Tecfidera (dimethyl fumarate) 60
Tysabri (natalizumab) 25
Ampyra (Fampyra) 0
Others 0